Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve access to lifesaving therapies. Payers and politicians must be persuaded to loosen their purse strings – and open their minds.

Novo raises its top- and bottom-line guidance as it prioritizes volume over price.

Buntanetap has flopped in Alzheimer’s disease, making an upcoming Parkinson’s trial a must-win. But there are reasons to doubt the outcome of this study, and Annovis is running out of money.

A hit with Enhertu in an earlier setting in HER2-low breast cancer patients, and in ultralow expressers, heightens expectations.

Pharma groups must decide how best to invest their cash to generate the biggest returns, and while huge sums can be made with luck and good judgement, strategic missteps can have far-reaching consequences.

The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.